Comparative Pharmacology
Head-to-head clinical analysis: HC 1 versus TOPICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HC 1 versus TOPICORT.
HC #1 vs TOPICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing production of prostaglandins and leukotrienes, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
Apply a thin film to the affected skin areas twice daily. Maximum adult dose: 50 g/week. Not for use on the face, axillae, or groin. Do not use under occlusive dressings.
None Documented
None Documented
2–4 hours (terminal); prolonged in renal impairment.
Terminal elimination half-life: 2-4 hours for parent drug; clinical effect lasts longer due to receptor binding
Renal: 90% as unchanged drug; fecal: 10%.
Renal (metabolites): ~75%; Fecal: ~25%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid